Pharmacokinetics-pharmacodynamics of tazobactam in combination with cefepime in an in vitro infection model

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 12, 2017, Pages

  VanScoy, Brian D ^a   Tenero, David ^b   Turner, Simon ^c   Livermore, David M ^d   McCauley, Jennifer ^a   Conde, Haley ^a   Bhavnani, Sujata M ^a   Rubino, Christopher M ^a   Ambrose, Paul G ^a  

^a INSTITUTE FOR CLINICAL PHARMACODYNAMICS   (United States)

^b GLAXOSMITHKLINE   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Cefepime; Pharmacokinetics pharmacodynamics; Tazobactam

Indexed keywords

ACRA PROTEIN; BETA LACTAMASE AMPC; BETA LACTAMASE CTX M; BETA LACTAMASE CTX M 15; CEFEPIME; OUTER MEMBRANE PROTEIN; OUTER MEMBRANE PROTEIN C; TAZOBACTAM; UNCLASSIFIED DRUG; ACRA PROTEIN, E COLI; AMPC BETA-LACTAMASES; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; BETA-LACTAMASE CTX-M-15; CARRIER PROTEIN; CEPHALOSPORIN DERIVATIVE; ESCHERICHIA COLI PROTEIN; LIPOPROTEIN; PENICILLANIC ACID;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; CELL KILLING; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG ELIMINATION; EC50; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING KLEBSIELLA PNEUMONIAE; IN VITRO STUDY; INFECTION; KLEBSIELLA PNEUMONIAE; MONOTHERAPY; MUTATION RATE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; WHOLE GENOME SEQUENCING; ANALOGS AND DERIVATIVES; BIOLOGICAL MODEL; COMBINATION DRUG THERAPY; DRUG EFFECT; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE; PHYSIOLOGY;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; CEPHALOSPORINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; KLEBSIELLA PNEUMONIAE; LIPOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; PENICILLANIC ACID;

EID: 84976889962     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01052-17     Document Type: Article

References (14)

1. Gould IM, Ansari A, Harvey G, Douglas JG, Smith CC, Reid TM. 1991. Piperacillin/tazobactam in the treatment of serious acute soft tissue infection. Drugs Exp Clin 17:187–190.
2. Merck & Co, Inc. 2016. Zerbaxa for injection package insert. Merck & Co, Inc, Whitehouse Station, NJ.
3. Ghafur A, Tayade A, Kannaian P. 2012. Clinical profile of patients treated with cefepime/tazobactam: a new -lactam/-lactamase inhibitor combination. J Microbiol Infect Dis 3:79–86. https://doi.org/10.5799/ahinjs.02.2012.03.0049.
4. Laws A, Page M. 1996. The chemistry and structure-activity relationships of C3-quartenary ammonium cephem antibiotics. J Chemother 8:7–22.
5. Rao SP, Rama PS, Gurushanthappa V, Manipura R, Srinivasan K. 2014. Extended-spectrum beta-lactamases producing Escherichia coli and Klebsiella pneumonia: a multi-centric study across Karnataka. J Lab Physicians 6:7–13. https://doi.org/10.4103/0974-2727.129083.
6. Kaur R, Gautam V, Singhal L, Ray P. 2014. Antimicrobial activity of cefepime-tazobactam combination tested against clinical isolates of Enterobacteriaceae. J Antibiot (Tokyo) 67:603–604. https://doi.org/10.1038/ja.2014.45.
7. VanScoy B, Mendes RE, Nicasio AM, Castanheira M, Bulik CC, Okusanya OO, Bhavnani SM, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG. 2013. Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model. Antimicrob Agents Chemother 57:2809–2814. https://doi.org/10.1128/AAC.02513-12.
8. VanScoy B, Mendes RE, McCauley J, Bhavnani SM, Bulik CC, Okusanya OO, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG. 2013. Pharmacological basis of -lactamase inhibitor therapeutics: tazobactam in combination with ceftolozane. Antimicrob Agents Chemother 57:5924–5930. https://doi.org/10.1128/AAC.00656-13.
9. Yamana T, Tsuji A. 1976. Comparative stability of cephalosporins in aqueous solution: kinetics and mechanisms of degradation. J Pharm Sci 65:1563–1574. https://doi.org/10.1002/jps.2600651104.
10. Nikaido H, Liu W, Rosenberg EY. 1990. Outer membrane permeability and beta-lactamase stability of dipolar ionic cephalosporins containing methoxyimino substituents. Antimicrob Agents Chemother 34:337–342. https://doi.org/10.1128/AAC.34.2.337.
11. Clinical and Laboratory Standards Institute. 2015. Performance standards for antimicrobial susceptibility testing. Standard M100-S25, 25th supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
12. Garrison MW, Vance-Bryan K, Larson TA, Toscano JP, Rotschafer JC. 1990. Assessment of effects of protein binding on daptomycin and vancomy-cin killing of Staphylococcus aureus by using an in vitro pharmacody-namic model. Antimicrob Agents Chemother 34:1925–1931. https://doi.org/10.1128/AAC.34.10.1925.
13. Hospira, Inc. 2012. Maxipime package insert. Hospira, Inc, Lake Forest, IL.
14. Miller B, Hershberger E, Benzinger D, Trinh M, Friedland I. 2012. Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses. Antimicrob Agents Chemother 56:3086–3091. https://doi.org/10.1128/AAC.06349-11.